A Variant of Uncertain Significance on a Cancer Gene Test

A variant of uncertain significance (VUS) is an uncertain genetic test result that identifies a DNA change whose effect on health remains unknown. The evidence may be incomplete or conflicting, so the finding doesn’t establish inherited cancer risk.

When you’re facing a life-threatening disease or living in remission, another unanswered question can feel heavy. You deserve a clear explanation of what this uncertainty means, beginning with what the laboratory found.

Key Takeaways

  • A variant of uncertain significance (VUS) is a DNA change whose effect on health remains unknown because the evidence is incomplete or conflicting. It doesn’t establish inherited cancer risk or show that the change caused your cancer.
  • A VUS alone shouldn’t guide treatment, preventive surgery, or intensified screening. Your diagnosis, personal and family history, treatment history, and other findings guide care.
  • A laboratory may reclassify a VUS when new evidence becomes available. Most reclassified VUS move toward benign or likely benign, but this doesn’t mean every VUS will change.
  • Inherited testing looks for DNA changes present throughout the body, while tumor testing examines changes in cancer cells. A tumor finding alone doesn’t establish an inherited change.

What does a variant of uncertain significance tell you?

A genetic variant is a difference in your DNA sequence. Many differences cause no health problems. Others interfere with how genes work and increase disease risk.

Variant interpretation weighs the evidence about a particular change, and variant classification reflects that evidence. A VUS describes the limits of that evidence, rather than the seriousness of your illness.

A watercolor still life with a folded test report, a blue DNA model, and a family tree sketch.

The 2015 ACMG and AMP guidelines use five categories for inherited-disease testing.

ClassificationPlain-language meaning
PathogenicEvidence supports a disease-causing role.
Likely pathogenicEvidence strongly supports a disease-causing role.
Variant of uncertain significanceEvidence remains insufficient or conflicting.
Likely benignEvidence strongly supports a harmless role.
BenignEvidence supports a harmless role.

A pathogenic finding has evidence supporting a disease-causing role, while a VUS lacks enough evidence for that conclusion.

In these guidelines, “likely” means greater than 90% confidence in the classification.

That confidence describes the laboratory’s conclusion about the variant. It doesn’t mean you have a greater than 90% chance of developing cancer.

What should a VUS change about your care?

Treatment and screening decisions

Clinicians shouldn’t let a VUS alone drive a treatment decision, preventive surgery, or intensified screening. Your diagnosis, personal and family history, treatment history, and other findings guide those decisions.

The National Cancer Institute’s genetic testing guidance explains why uncertain findings generally shouldn’t guide health care decisions.

Continue the care plan your team recommends for your circumstances. A VUS doesn’t cancel screening that your family history already warrants.

What the result cannot explain

A VUS doesn’t establish an inherited cancer syndrome or prove that this particular DNA change caused your cancer. It also doesn’t rule out an inherited risk that testing hasn’t identified.

Nor does it tell you whether treatment will work or whether cancer will return. Those questions require other information.

How do you carry an answer that still leaves questions? Start by separating what your report establishes from what fear might add. Your genetic counselor can help you make that distinction.

How common are uncertain results, and can they change?

More genes can mean more unanswered questions

An American College of Medical Genetics and Genomics (ACMG) resource reports a VUS in roughly one-third of multigene-panel reports. A panel examines several genes during one test.

That figure doesn’t apply equally to every test or population. The number of genes a laboratory examines affects its opportunity to find changes that scientists don’t yet understand.

An uncertain finding therefore doesn’t mean the test failed. The laboratory detected a change but lacks enough evidence to explain its health effects confidently.

Reclassification can bring a clearer answer

A laboratory may later change a variant’s classification as additional information becomes available. Scientists call this reclassification.

Reclassifying can involve evidence from population databases, which show how often a change appears, and functional studies, which test how it affects gene function. This evidence helps assess pathogenicity, a variant’s potential to cause disease, but can’t predict an individual’s cancer outcome or guarantee a classification change.

The ACMG germline VUS resource reports that 75% to 95% of reclassified VUS move toward benign or likely benign.

The denominator matters: those percentages describe variants that received a new classification, not every VUS. They don’t promise that your particular result will change.

Laboratories share genetic findings and classifications through ClinVar, a public database at the National Center for Biotechnology Information. ClinVar submissions help researchers and clinicians bring evidence together across institutions, but they don’t replace review of your laboratory report.

Inherited testing and tumor testing answer different questions

Cancer gene tests don’t all look for the same thing. Understanding which test you had helps you understand the report.

Inherited, or germline, testing looks for DNA changes present throughout the body that someone could pass to children. Laboratories commonly use the five-category framework above.

Tumor, or somatic, testing examines changes within cancer cells, often to identify possible treatment targets. A tumor finding alone doesn’t establish that you carry an inherited change.

A tumor suppressor gene normally helps limit cell growth. Changes in an oncogene can promote cell growth, but gene type alone doesn’t establish what a finding means for your care.

Our explanation of hereditary and tumor genetic testing describes this distinction.

The 2017 joint cancer-testing consensus from AMP, ASCO, and CAP uses four tiers of clinical significance, meaning how a finding relates to clinical care. Tier III covers variants of unknown clinical significance. Ask your team which framework your report uses.

Bring the report into a conversation

You don’t need to master genetics before asking for help. A genetic counselor can explain the finding alongside your medical and family history.

Keep a copy of the laboratory report. Agree with the ordering clinician on who will receive any amended report and how your care team will communicate an update.

These questions can help:

  1. Does this result concern inherited risk, changes in my tumor, or both?
  2. Which parts of my personal and family history guide my care despite this uncertainty?
  3. Who will explain any future change in the laboratory’s classification?
  4. Could testing my biological parents or other family members help clarify how this change arose?

A de novo change arises for the first time in a person; an inherited variant is passed down from a parent. Family testing can sometimes help a genetics team interpret a result, but it doesn’t prove when or how a change arose. This differs from cascade testing, which generally tests relatives after a disease-causing family finding is confirmed.

Our guidance on preparing for treatment decisions offers additional questions for discussing recommendations and evidence.

Tell your team if the uncertainty interferes with sleep or daily life. Emotional support belongs in this conversation, too.

Frequently Asked Questions

What does a variant of uncertain significance mean?

A VUS is a DNA change whose effect on health remains unknown because the evidence is insufficient or conflicting. It doesn’t establish that the change causes cancer or increases inherited cancer risk.

Should a VUS change my treatment or screening?

A VUS alone shouldn’t drive treatment, preventive surgery, or intensified screening. Your care team should consider your diagnosis, personal and family history, treatment history, and other findings.

Can a VUS classification change?

Yes. A laboratory may reclassify a variant when new evidence becomes available, but a change isn’t guaranteed. Among VUS that are reclassified, 75% to 95% move toward benign or likely benign.

What’s the difference between inherited testing and tumor testing?

Inherited, or germline, testing looks for DNA changes present throughout the body that someone could pass to children. Tumor, or somatic, testing examines changes in cancer cells, and a tumor finding alone doesn’t establish an inherited change.

Can testing family members help explain a VUS?

Testing biological parents or other family members can sometimes help a genetics team interpret a result. It doesn’t prove when or how the change arose.

Let evidence guide the next step

A variant of uncertain significance leaves a question open. Your care can still move forward using your diagnosis, medical history, and findings that have clear meaning.

There is courage in asking someone to explain a report again. You don’t have to carry its uncertainty alone, and you don’t have to treat it as a prediction. Keep your care grounded in what the evidence supports.

Add a Comment

Verified by MonsterInsights